MAZE advances Phase II kidney, metabolic studies; cash runway into 2029
MAZE said three clinical programs are advancing, including MZE829 with promising phase II results in AMKD and MZE782 progressing in PKU and CKD. HORIZON study adjustments target balanced enrollment; cash runway extends into 2029.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.